SL22105: Specialised integrated unit 1: immunity, inflammation and infection and gastrointestinal disease
[Page last updated: 11 January 2024]
| Academic Year: | 2023/24 |
| Owning Department/School: | Department of Life Sciences |
| Credits: | 15 [equivalent to 30 CATS credits] |
| Notional Study Hours: | 300 |
| Level: | Intermediate (FHEQ level 5) |
| Period: |
|
| Assessment Summary: | CWOG 15%, CWSI 15%, EXCB 70% |
| Assessment Detail: |
|
| Supplementary Assessment: |
|
| Requisites: | |
| Learning Outcomes: |
By the end of the unit, you will be able to:
1. Describe the aetiology, epidemiology, pathophysiology and clinical symptoms of immune disorders, inflammatory disorders, infection, GI and liver diseases and how they are diagnosed and treated.
2. Describe the formulation and requirements of solid and liquid dosage forms and their application.
3. Describe the fundamentals of medicines design for use in gastrointestinal diseases.
4. Explain how GI and liver physiology and disease affect drug therapy, formulation performance and drug efficacy and safety.
5. Discriminate between the pharmacological actions of drugs acting at sites in the GI tract.
6. Explain the processes of GI absorption, metabolism and transport mediated ADME of drugs and their relevance in therapy outcomes.
7. Describe the formulation and requirements of parenteral dosage forms and their application in treating infectious diseases.
8. Describe the natural host immunological response to infectious agents and explain how inappropriate responses (to non-pathogenic organisms) and failure in self-tolerance can lead to disease.
9. Explain the pharmacology of therapeutic agents used in the treatment of infectious and inflammatory conditions.
10. Classify and identify bacteria, fungi, viruses, protozoa and helminths to enable appropriate selection of antimicrobial treatment and prevention strategies.
11. Discuss effective antimicrobial stewardship through knowledge of antibiotic design, clinical usage and emerging resistance.
12. Explain treatment effectiveness and rationale for disease prevention strategies through the knowledge of antimicrobial lifecycles, pathogenicity and epidemiology.
13. Apply knowledge of immunology to describe current processes e.g. vaccinations for disease prevention and eradication and use of biologics as novel therapeutic targets.
14. Identify and utilise the evidence base for treatment of immune disorders, inflammatory disease and infection.
15. Describe the role of the pharmacist in prescribing, administering and monitoring medication for patients with conditions studied in this unit.
16. Make appropriate clinical decisions in support of patients with conditions studied in this unit.
17. Apply structured consultation skills to the conditions studied in this unit. |
| Synopsis: | This unit will provide you with comprehensive, integrated understanding of the design and development of medicines, their pharmacological actions in the body and the evidence-based approach to treatment of patients with the aim of promoting safe and effective outcomes in immune disorders, inflammatory disease, infection, gastrointestinal and liver diseases. |
| Content: | Pre-formulation - Solid form selection, crystallisation and particle engineering, salts and salt selection, polymorphic forms
Drug solubility and dissolution rate. Methods for solubility enhancement
Drug delivery to the GI tract. Formulation and physiological requirements
Drug absorption through different GI routes, physiological effects on oral absorption
Liquid formulations (solubility enhancement, micelles, HLB)
Drug transporters in ADME. Therapy implications
Manufacturing environment and contamination
Protein analysis, diagnostics tests, urinalysis, ELISA, flow cytometry
Pharmacokinetics of anti-infectives and therapeutic drug monitoring
Parenteral drug administration
Formulation and requirements of parenterals
The pharmacology of muscarinic and histamine receptors
Gastric secretion - proton pump inhibitors, H2 antagonists and antacids
Nausea and vomiting, anti-emetic drugs
Modes of action of antibiotics, antivirals, antifungals and antimalarials
Immune system - Innate immunity, adaptive immunity, T&B cells, antibodies, immune diseases
The management of acute and chronic inflammation and pain
Common acute and inflammatory diseases including RA
Immunosuppression
Drug metabolism: introduction, Cytochromes P450, families of enzymes, m - SAR in glucuronidation, tracking metabolism
Drug metabolism: Role of liver disease, drug interactions and non-linear kinetics in therapy
Drug Design - Classical SAR and QSAR
Introduction to natural products as medicines
Dyspepsia, Helicobacter pylori, peptic ulcer disease
Gastrointestinal motility, constipation and diarrhoea, laxatives, anti-motility agents
Irritable bowel syndrome
Fundamentals of hepatic dysfunction & liver disease
Drug design of antibiotics, antivirals, antifungals, antimalarials, steroids
New strategic approaches to antibiotic development and deployment
Antibiotic resistance and antibiotic stewardship
Parasitic infestations
Clinical use of antibacterial, antiviral, antifungal, anti-protozoal drugs
Vaccines
Practical microbiology
Clinical decision-making
Simulation and practice-based learning |
| Course availability: |
SL22105 is a Must Pass Unit on the following courses:Department of Life Sciences
|
Notes:
|